LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Groundbreaking Study Points to Crucial Gap in Children’s Clinical Testing

By LabMedica International staff writers
Posted on 03 May 2022
Print article
Image: Study demonstrates significant inconsistencies with pediatric reference interval (Photo courtesy of Unsplash)
Image: Study demonstrates significant inconsistencies with pediatric reference interval (Photo courtesy of Unsplash)

To correctly interpret clinical test results for pediatric patients, physicians must evaluate results within the context of reference intervals - the range of normal test values appropriate for the age, stage of development, ethnicity, and gender of a child. Now, a groundbreaking study has demonstrated significant inconsistencies with pediatric reference intervals, which are essential to high quality pediatric medical testing.

The study completed by laboratory medicine experts at the American Association for Clinical Chemistry (AACC, Washington, DC, USA) identifies some of the most pressing issues in this area, thereby paving the way for the medical community to develop more reliable pediatric reference intervals and vastly improve children’s medical care. The pediatric reference intervals in use today are highly inconsistent for a broad range of common clinical laboratory tests, a problem that puts children at risk for inappropriate or even harmful medical care. For example, imprecise reference intervals can lead to a physician missing that a child has a serious medical condition and failing to administer treatment in time.

With this in mind, a team of AACC scientists analyzed the reference intervals for several common and important pediatric tests. These reference intervals included those for free thyroxine, thyrotropin, ferritin, hemoglobin, and IGF-1, all of which are crucial for early identification and treatment of various disorders that impact pediatric cognitive and physical development; cystatin C, which is used to predict end-stage kidney disease in children; estradiol (a form of estrogen); and testosterone. The researchers examined the numerous reference intervals for each of these tests that are published in the scientific literature, as well as those developed and used by individual clinical labs.

From this, the team found that many of these pediatric reference intervals are inappropriate for assessing a child’s health or monitoring treatment. The reference intervals for free thyroxine, thyrotropin, ferritin, cystatin C, estradiol, and testosterone were particularly inconsistent, especially during developmental stages where children undergo rapid biochemical changes. As just one example, some pediatric reference intervals for free thyroxine and thyrotropin fail to capture the surge in these two hormones that occurs in the first few days of life, which could lead to incorrect diagnoses of thyroid diseases in newborns. Inconsistencies such as this are due, in part, to the high variability in the age groups used to represent certain life stages during pediatric reference interval development - a finding that is essential to improving these reference intervals in the future.

“There is a need to correctly describe the biochemistry of child development, as well as to identify strategies to develop accurate and consistent pediatric reference intervals for improved pediatric care,” said Hubert W. Vesper, PhD, an AACC member and director of clinical standardization programs at CDC, who led the team of AACC scientists. “Continued communication and collaboration between clinicians and their laboratory colleagues ensures appropriate clinical test interpretation and patient assessment and remains essential to effective implementation of common pediatric reference intervals.”

Related Links:
AACC 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more